A Breakdown is on the Horizon for Karyopharm Therapeutics

NASDAQ: KPTI | Karyopharm Therapeutics Inc. News, Ratings, and Charts

KPTI – A support level has formed in the chart of Karyopharm Therapeutics Inc (KPTI). If the stock moves under this level, a breakdown could soon occur. Read more to learn to how to take advantage of this trade.

A key support level has emerged in the chart of Karyopharm Therapeutics Inc (KPTI).  If the stock moves under this level, a breakdown could occur.

KPTI is a pharmaceutical company. The company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer.

While KPTI’s earnings were essentially in line with the previous year’s figure, revenues increased to $21.3 million from $13.2 million. Its Xpovio sales were driven by new prescriber accounts and an increase in average refill rate. The second line multiple myeloma indication for Xpovio should be added later this year.

The company had $263 million in cash as of the end of the latest quarter, compared with only $128 million in long-term debt. Though KPTI is not profitable yet, with a negative net margin.

While earnings are still underwater, revenue has surged an average of 224.9% over the past five years and is expected to rise 74.9% this year. The stock appears undervalued to its industry with a Price to Sales ratio of 11.6.

The stock has shown mixed performance figures over the past year, along with mixed component grades and an overall rating of Neutral in our POWR Ratings system.

Take a look at the 1-year chart of KPTI below with added notations:

  Chart of KPTI provided by TradingView

KPTI has formed a major level of support in the $14 area (green) over the past year. The stock looks like it may be falling back down to that $14 level again, and if so, another bounce may follow. However, if the support were to break, lower prices would likely follow for KPTI.

If the stock were to break below the $14 support level, a short position could be entered with the expectation of a breakdown.

Want to Discover More Great Trades?

I have explored virtually every flavor of technical analysis and chart pattern known to mankind. The sad fact is that the vast majority of them don’t work at all.

That is why I recently put together this special report to help investors focus on the only 5 chart patterns that matter…the ones that lead to the most timely and profitable stock trades. Click below to get your copy now!

5 WINNING Stock Chart Patterns

Have a good trading day!

Good luck!

Christian Tharp, CMT

@cmtstockcoach


KPTI shares were trading at $15.06 per share on Monday morning, down $0.17 (-1.12%). Year-to-date, KPTI has declined -2.71%, versus a -0.47% rise in the benchmark S&P 500 index during the same period.


About the Author: christian


Christian is an expert stock market coach at the Adam Mesh Trading Group who has mentored more than 4,000 traders and investors. He is a professional technical analyst that is a certified Chartered Market Technician (CMT), which is a designation awarded by the CMT Association. Christian is also the author of the daily online newsletter Todays Big Stock. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
KPTIGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Updated 2024 Stock Market Outlook

The bull market continues to rage on with the S&P 500 (SPY) making new highs. That is the past...the question is what does the future hold? That is why 44 year investment veteran Steve Reitmeister provides this updated 2024 Stock Market Outlook to help you carve a path to outperformance the rest of the year. Read on below for the full story...

Top 4 Tech Giants Poised for Explosive Growth

Fueled by the ever-growing demand for advanced technological solutions across various sectors and ongoing innovation, the tech industry has robust growth prospects. Thus, it could be wise to invest in top tech stocks Dropbox (DBX), TTM Technologies (TTMI), Lantronix (LTRX) and AstroNova (ALOT) for potential growth. Continue reading…

3 Top Rated Software Stocks to Streamline Your Investments

The software industry is thriving with soaring demand, presenting ample investment opportunities. So, fundamentally solid software stocks ServiceNow (NOW), Autodesk (ADSK), and Docebo (DCBO) might be ideal buys for promising returns. Read on...

Biotech Investors: Should You Buy, Hold, or Sell Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR)?

Despite facing several challenges, the biotech sector thrives due to growing demand for effective treatments, consistent innovations, and a sustained demand for high-quality drugs and therapies. Let's assess whether one should Buy, Hold, or Sell biotech stocks Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR). Keep reading...

Investor Alert: “Buy the Rumor, Sell the News!”

Everyone knows that the Fed is going to cut rates at some point this year. That is the worst kept secret on the planet helping to explain how we keep making new highs for the for the S&P 500 (SPY). Unfortunately that creates an interesting predicament for stocks after rates are cut. Plus another hurdle in the 2024 Presidential election. Steve Reitmeister is here to share his insights on the market outlook along with a preview of his top 12 stocks to outperform. Read on for more...

Read More Stories

More Karyopharm Therapeutics Inc. (KPTI) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All KPTI News